[
    {
        "title": "The Top 3 Risks Alibaba Investors Should Not Ignore",
        "url": "https://www.fool.com/investing/2025/12/08/the-top-3-risks-alibaba-investors-should-not-ignor/?source=iedfolrf0000001",
        "source": "The Motley Fool",
        "image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F845746%2Fshopping-4.jpg&w=1200&op=resize",
        "published_utc": "2025-12-09T02:30:00Z"
    },
    {
        "title": "Nvidia Stock Pops After President Trump OKs Sales of New H200 AI Chips to China",
        "url": "https://www.fool.com/investing/2025/12/08/nvidia-stock-pops-after-trump-oks-sales-of-new-h20/?source=iedfolrf0000001",
        "source": "The Motley Fool",
        "image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F846182%2Fnvda-stock-ai-chips-export-to-china-h200-trump-ok-greenlights.png&w=1200&op=resize",
        "published_utc": "2025-12-09T02:28:46Z"
    },
    {
        "title": "Rio2 Announces Upsize of Previously Announced Bought Deal Financing to C$166 Million",
        "url": "https://www.globenewswire.com/news-release/2025/12/09/3202032/0/en/Rio2-Announces-Upsize-of-Previously-Announced-Bought-Deal-Financing-to-C-166-Million.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/ae383b40-539b-484f-a493-3b9b4855684f",
        "published_utc": "2025-12-09T02:08:00Z"
    },
    {
        "title": "Netcapital Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)",
        "url": "https://www.globenewswire.com/news-release/2025/12/09/3202030/0/en/Netcapital-Inc-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/5380deaa-47b8-4805-8ada-9528988af995",
        "published_utc": "2025-12-09T01:31:00Z"
    },
    {
        "title": "Should You Buy XRP While It's Under $3? Here's What Smart Investors Should Know.",
        "url": "https://www.fool.com/investing/2025/12/08/should-you-buy-xrp-under-3-smart-investors-know/?source=iedfolrf0000001",
        "source": "The Motley Fool",
        "image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F842646%2Finvestor-taking-notes-stock-charts-1200x675-128554e.jpg&w=1200&op=resize",
        "published_utc": "2025-12-09T01:30:00Z"
    },
    {
        "title": "Rosen Law Firm Encourages Nidec Corporation Investors to Inquire About Securities Class Action Investigation - NJDCY",
        "url": "https://www.benzinga.com/pressreleases/25/12/n49272441/rosen-law-firm-encourages-nidec-corporation-investors-to-inquire-about-securities-class-action-inv?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel",
        "source": "Benzinga",
        "image": "https://www.benzinga.com/next-assets/images/benzinga-schema-image-default.png",
        "published_utc": "2025-12-09T01:23:00Z"
    },
    {
        "title": "ROSEN, LEADING INVESTOR COUNSEL, Encourages DeFi Technologies, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action \u2013 DEFT",
        "url": "https://www.globenewswire.com/news-release/2025/12/09/3202026/673/en/ROSEN-LEADING-INVESTOR-COUNSEL-Encourages-DeFi-Technologies-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-DEFT.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/745335af-3a3a-4fb5-84c0-fdedc9adf092",
        "published_utc": "2025-12-09T01:07:00Z"
    },
    {
        "title": "Here's Why Rocket Mortgage Is a Buy Before the End of 2025",
        "url": "https://www.fool.com/investing/2025/12/08/heres-why-rocket-mortgage-is-a-buy-before-the-end/?source=iedfolrf0000001",
        "source": "The Motley Fool",
        "image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F845805%2Fperson-handing-house-key-to-another-person-in-front-of-new-home-real-estate-house-mortgage-homeowner.jpg&w=1200&op=resize",
        "published_utc": "2025-12-09T01:05:00Z"
    },
    {
        "title": "ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP",
        "url": "https://www.globenewswire.com/news-release/2025/12/09/3202022/0/en/ASH-2025-Ascentage-Pharma-Presents-Four-Year-Follow-Up-Data-from-Registrational-Phase-II-Study-of-Olverembatinib-Reaffirming-Differentiated-Long-Term-Efficacy-and-Safety-in-TKI-Res.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/b9623a51-a13b-4b80-8152-61d5014f4a0a",
        "published_utc": "2025-12-09T00:45:00Z"
    },
    {
        "title": "ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%",
        "url": "https://www.globenewswire.com/news-release/2025/12/09/3202021/0/en/ASH-2025-Ascentage-Pharma-Presents-First-Dataset-from-Phase-III-POLARIS-1-Study-of-Olverembatinib-in-Newly-Diagnosed-Ph-ALL-Shows-a-Best-MRD-Negativity-CR-Rate-Exceeding-60.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/b9623a51-a13b-4b80-8152-61d5014f4a0a",
        "published_utc": "2025-12-09T00:45:00Z"
    },
    {
        "title": "ASH 2025 | Updated Data for Ascentage Pharma\u2018s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment",
        "url": "https://www.globenewswire.com/news-release/2025/12/09/3202020/0/en/ASH-2025-Updated-Data-for-Ascentage-Pharma-s-Olverembatinib-in-Second-Line-CML-CP-Showing-Encouraging-Potential-for-Early-Line-Treatment.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/b9623a51-a13b-4b80-8152-61d5014f4a0a",
        "published_utc": "2025-12-09T00:45:00Z"
    },
    {
        "title": "RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO",
        "url": "https://www.globenewswire.com/news-release/2025/12/09/3202019/0/en/RetinalGenix-Technologies-Agrees-To-Hire-M-Cory-Zwerling-as-CFO-Interim-COO.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/08bcd83b-5684-49d3-bdb6-809c942eacea",
        "published_utc": "2025-12-09T00:43:00Z"
    },
    {
        "title": "Star Group, L.P. Reports Fiscal 2025 Full Year and Fourth Quarter Results",
        "url": "https://www.globenewswire.com/news-release/2025/12/09/3202018/0/en/Star-Group-L-P-Reports-Fiscal-2025-Full-Year-and-Fourth-Quarter-Results.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/0dba9914-8cc6-419e-bbfd-a2a7c1cbd782",
        "published_utc": "2025-12-09T00:22:00Z"
    },
    {
        "title": "UPDATE - Broadway Star Morgan Dudley Joins Stargaze as Creative Advisor",
        "url": "https://www.globenewswire.com/news-release/2025/12/08/3202017/0/en/UPDATE-Broadway-Star-Morgan-Dudley-Joins-Stargaze-as-Creative-Advisor.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/0748219f-56e8-4f5f-8b43-0a84683ef568",
        "published_utc": "2025-12-08T23:53:00Z"
    },
    {
        "title": "ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm \u2013 TLX",
        "url": "https://www.globenewswire.com/news-release/2025/12/08/3202015/673/en/ROSEN-GLOBAL-INVESTOR-COUNSEL-Encourages-Telix-Pharmaceuticals-Ltd-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-First-Filed-by-the-Firm-TLX.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/745335af-3a3a-4fb5-84c0-fdedc9adf092",
        "published_utc": "2025-12-08T23:45:00Z"
    },
    {
        "title": "Is Citigroup Stock a Buy Now?",
        "url": "https://www.fool.com/investing/2025/12/08/is-citigroup-stock-a-buy-now/?source=iedfolrf0000001",
        "source": "The Motley Fool",
        "image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F845763%2F24_09_26-a-person-holding-a-sign-that-says-warning-attention-please-_mf-dload-gettyimages-1639158401-1201x800-5b2df79.jpg&w=1200&op=resize",
        "published_utc": "2025-12-08T23:34:00Z"
    },
    {
        "title": "Why Wave Life Sciences Stock Vaulted 146% Higher on Monday",
        "url": "https://www.fool.com/investing/2025/12/08/why-wave-life-sciences-stock-vaulted-146-higher-on/?source=iedfolrf0000001",
        "source": "The Motley Fool",
        "image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F846164%2Fpatient-being-weighed-by-a-medical-professional.jpg&w=1200&op=resize",
        "published_utc": "2025-12-08T23:30:58Z"
    },
    {
        "title": "\u201cLEQEMBI\u00ae\u201d (lecanemab) for the Treatment of Early Alzheimer\u2019s Disease Included in China\u2019s Commercial Insurance Innovative Drug List",
        "url": "https://www.globenewswire.com/news-release/2025/12/08/3202014/0/en/LEQEMBI-lecanemab-for-the-Treatment-of-Early-Alzheimer-s-Disease-Included-in-China-s-Commercial-Insurance-Innovative-Drug-List.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/80f9c524-3da2-4583-a763-0dad931fa182",
        "published_utc": "2025-12-08T23:30:00Z"
    },
    {
        "title": "Trump May Require '60 Minutes' Apology Before Blessing Paramount's Warner Bid",
        "url": "https://www.benzinga.com/news/politics/25/12/49271773/trump-may-require-60-minutes-apology-before-blessing-paramounts-warner-bid?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel",
        "source": "Benzinga",
        "image": "https://cdn.benzinga.com/files/images/story/2025/12/08/February-4--2023--Brazil--In-This-Photo-.jpeg?width=1200&height=800&fit=crop",
        "published_utc": "2025-12-08T23:27:14Z"
    },
    {
        "title": "ROSEN, LEADING TRIAL ATTORNEYS, Encourages Synopsys, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SNPS",
        "url": "https://www.globenewswire.com/news-release/2025/12/08/3202013/673/en/ROSEN-LEADING-TRIAL-ATTORNEYS-Encourages-Synopsys-Inc-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-SNPS.html",
        "source": "GlobeNewswire Inc.",
        "image": "https://ml.globenewswire.com/Resource/Download/745335af-3a3a-4fb5-84c0-fdedc9adf092",
        "published_utc": "2025-12-08T23:17:00Z"
    }
]